Coverage Initiated by HC Wainwright for Arena Pharmaceuticals (NASDAQ:ARNA)

0
31

Stock analysts at HC Wainwright initiated coverage on shares of  Arena Pharmaceuticals (NASDAQ:ARNA) in a report issued on Monday. The brokerage set a Buy rating on the Medical stock. A price-to-earnings ratio of #N/A and a beta of 1.39. Arena Pharmaceuticals has a twelve month low $32.95 of  and a twelve month high of $69.75.

Shares of Arena Pharmaceuticals traded down -$2.38 on Monday, reaching $63.54. 281705 shares of the stock traded hands, compared to its average volume of 1044015. Shares of Arena Pharmaceuticals were trading at $63.54 on Monday mid-day. The firm’s 50 day moving average is $$56.95 and its 200 day moving average is $49.35.Arena Pharmaceuticals  has a 12 month low of $63.20 and a 12 month high of $69.75. While on yearly highs and lows, Arena Pharmaceuticals’s today has traded high as $66.93 and has touched $63.20 on the downward trend. See More Analyst Rating at: RATING

Arena Pharmaceuticals Earnings and What to expect: 

Arena Pharmaceuticals last announced its earnings results on May 7th, 2020. The biopharmaceutical company reported ($2.00) EPS for the quarter, topping the consensus estimate of ($2.28) by $0.28. The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $1.58 million. Its revenue for the quarter was down 100.0% on a year-over-year basis. Arena Pharmaceuticals has generated $7.69 earnings per share over the last year. Arena Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, August 5th, 2020 based off prior year’s report dates.

Earnings for Arena Pharmaceuticals are expected to grow in the coming year, from ($8.78) to ($5.79) per share. The P/E ratio of Arena Pharmaceuticals is -10.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Arena Pharmaceuticals is -10.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Arena Pharmaceuticals has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 3.05%
  • On 6/17/2020 Director Manmeet Singh Soni Sell 304 at average share price of $62.74 which equates to $19,072.96 in money value.
  • On 6/15/2020 Director Manmeet Singh Soni Sell 1,327 at average price of  $60.12 with total value of : Not Data Available
  • On 6/2/2020 CEO Amit Munshi Sell 50,000 at average price of  $65.00 with total value of : $3,250,000.00

Analyt at HC Wainwright other ratings :

Latest rating for Arena Pharmaceuticals by other brokers:

  • 6/29/2020 – Chiasma had its price target raised by analysts at HC Wainwright from $10.00 to $11.00. They now have a “buy” rating on the stock.
  • 6/29/2020 – Novavax had its price target raised by analysts at HC Wainwright from $50.00 to $101.00. They now have a “buy” rating on the stock.
  • 6/29/2020 – Gossamer Bio is now covered by analysts at HC Wainwright. They set a “buy” rating and a $31.00 price target on the stock.
  • 6/29/2020 – Inovio Pharmaceuticals was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating.

Arena Pharmaceuticals (NASDAQ:ARNA) Moving Average Technical Analysis

5 day Moving Average is $65.65 And 5 day price change is $1.73 (2.66%)  with average volume for 5 day average is 656,283. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $64.61 and 20 day price change is $8.15 (13.88%) and average 20 day moving volume is 885,366. 50 day moving average is $56.95  and 50 day price change is $17.12 ( 34.43%)  and with average volume for 50 days is : 825,284. 200 day moving average is $49.35  and 200 day price change is $14.27 (27.14%)  and with average volume for 200 days is : 577,023.

See More Analyst Rating at: RATING